Ceftobiprole medocaril (BAL5788) is the product of a joint development programme between Basilea Pharmaceutica AG and Cilag AG International (a Johnson & Johnson company).
-
Ceftobiprole medocaril (BAL5788) is an injectable anti-MRSA cephalosporin. -
S. aureus is a major cause of skin and soft tissue infections. -
Basilea Pharmaceutica's drug development pipeline. -
Ceftobiprole medocaril (BAL5788) is the product of a joint development... -
S. aureus can cause serious infections in hospitalised patients, the... -
Ceftobiprole has been approved for use in Canada and Ukraine under the name...
